Elevated Circulating Levels and Tissue Expression of Pentraxin 3 in Uremia: A Reflection of Endothelial Dysfunction
Open Access
- 3 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e63493
Abstract
Elevated systemic pentraxin 3 (PTX3) levels appear to be a powerful marker of inflammatory status and a superior outcome predictor in patients with chronic kidney disease (CKD). As previous data imply that PTX3 is involved in vascular pathology and that adipose tissue mass may influence circulating PTX3 levels, we aimed to study the importance of adipose tissue expression of PTX3 in the uremic milieu and its relation to endothelial dysfunction parameters. Plasma PTX3 and abdominal subcutaneous adipose tissue (SAT) PTX3 mRNA levels were quantified in 56 stage 5 CKD patients (median age 57 [range 25–75] years, 30 males) and 40 age and gender matched controls (median age 58 [range 20–79] years, 27 males). Associations between PTX3 measures and an extensive panel of clinical parameters, including surrogate markers of endothelial function, were assessed. Functional ex vivo studies on endothelial status and immunohistochemical staining for PTX3 were conducted in resistance subcutaneous arteries isolated from SAT. SAT PTX3 mRNA expression correlated with plasma PTX3 concentrations (rho = 0.54, p = 0.0001) and was increased (3.7 [0.4–70.3] vs. 1.2 [0.2–49.3] RQ, p = 0.02) in CKD patients with cardiovascular disease (CVD), but was not significantly different between patients and controls. The association to CVD was lost after adjustments. SAT PTX3 mRNA levels were independently correlated to asymmetric dimethylarginine and basal resistance artery tone developed after inhibition with nitric oxide synthase and cyclooxygenase (rho = −0.58, p = 0.002). Apparent positive PTX3 immunoreactivity was observed in both patient and control arteries. In conclusion, fat PTX3 mRNA levels are associated with measures of endothelial cell function in patients with CKD. PTX3 may be involved in adipose tissue-orchestrated mechanisms that are restricted to the uremic milieu and modify inflammation and vascular complications in CKD patients.Keywords
This publication has 62 references indexed in Scilit:
- Mechanisms of Endothelial Dysfunction in Resistance Arteries from Patients with End-Stage Renal DiseasePLOS ONE, 2012
- Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul StudyAmerican Heart Journal, 2012
- Inverse Relationship between the Inflammatory Marker Pentraxin-3, Fat Body Mass, and Abdominal Obesity in End-Stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2011
- Soluble TWEAK and PTX3 in Nondialysis CKD PatientsClinical Journal of the American Society of Nephrology, 2011
- The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest painThrombosis and Haemostasis, 2009
- Expression of Six Transmembrane Protein of Prostate 2 in Human Adipose Tissue Associates with Adiposity and Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2008
- Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease PatientClinical Journal of the American Society of Nephrology, 2008
- Oxidative Stress and Inflammation Are Associated with Adiposity in Moderate to Severe CKDJournal of the American Society of Nephrology, 2008
- Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial InfarctionCirculation, 2008
- The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular trapsJournal of Experimental Medicine, 2007